

## Original article

# The relationship between cognitive impairment and fatty acids and carnitine in hemodialysis patients

Baris Eser<sup>a,\*</sup>, Ibrahim Dogan<sup>a</sup>, Huseyin Kayadibi<sup>b</sup>

<sup>a</sup> Hitit University Faculty of Medicine, Department of Nephrology, 19200 Corum, Turkey

<sup>b</sup> Eskisehir Osmangazi University Faculty of Medicine, Department of Medical Biochemistry, Eskisehir, Turkey

## ARTICLE INFO

## Article history:

Received 24 August 2021

Accepted 20 February 2022

Available online 21 March 2022

## Keywords:

Cognitive impairment

Fatty acids

Hemodialysis

L-Carnitine

## ABSTRACT

**Background/Aim:** The prevalence of cognitive impairment (CI) is high in hemodialysis patients. In this study, the relationship between CI and serum carnitine, plasma omega-3, omega-6 and omega-3/omega-6 fatty acid ratio was evaluated in hemodialysis patients.

**Materials and methods:** Sixty two patients [male: 40 (64.5%), mean age 51 ± 13 years] were included in this cross-sectional study. Serum total and free-carnitine levels were determined by ELISA. Plasma omega-3 [eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)] and omega-6 [arachidonic acid (AA), dihomo gamma linoleic acid (DGLA)] levels were measured using LC-ESI-MS/MS. According to the Montreal Cognitive Assessment (MoCA) scores, ≤ 24 points were considered as CI. MoCA score ≤ 24 and > 24 were determined as Group 1 and Group 2, respectively.

**Results:** Group 1 had significantly higher AA + DGLA/EPA + DHA ratios and lower free-carnitine, DHA and EPA + DHA levels compared to Group 2 ( $P = 0.008$ ,  $P = 0.040$ ,  $P = 0.032$ ,  $P = 0.032$ , respectively). Group 1 had a statistically lower education level ( $P < 0.05$ ). Negative correlation was found between MoCA scores and AA + DGLA/EPA + DHA ratios ( $r_s = -0.284$ ,  $P = 0.026$ ). Free-carnitine levels were positively correlated with EPA and EPA + DHA levels ( $r_s = 0.278$ ,  $P = 0.030$  and  $r_s = 0.271$ ,  $P = 0.034$ , respectively), and negative correlated with AA + DGLA/EPA + DHA ratios ( $r_s = -0.414$ ,  $P = 0.001$ ). In multivariate logistic regression analysis, MoCA scores was associated with AA + DGLA/EPA + DHA ratio ( $P = 0.009$ ) and education level ( $P < 0.001$ ).

**Conclusion:** It was determined that high AA + DGLA/EPA + DHA ratio and low education level could be independent risk factors of the CI. It has been shown that free-carnitine level can have positive effects on plasma EPA + DHA and AA + DGLA distributions. Low omega-3 fatty acid levels may be associated with CI in hemodialysis patients, and low carnitine level may contribute partially to this process. In addition, cognitive education programs may have an effect on preventing CI in hemodialysis patients with low education levels.

© 2022 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\* Corresponding author.

E-mail address: [beser374@gmail.com](mailto:beser374@gmail.com) (B. Eser).

<https://doi.org/10.1016/j.nefro.2022.02.006>

0211-6995/© 2022 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Relación entre el deterioro cognitivo y los ácidos grasos y la carnitina en pacientes en hemodiálisis

### RESUMEN

#### Palabras clave:

Deterioro cognitivo  
Ácidos grasos  
Hemodiálisis  
L-carnitina

**Contexto/objetivo:** La prevalencia de deterioro cognitivo (CI) es alta en pacientes en hemodiálisis. En este estudio se evaluó la relación entre el CI y las proporciones de carnitina sérica, ácidos grasos omega-3, omega-6 y omega-3/omega-6 en plasma en pacientes en hemodiálisis.

**Materiales y métodos:** En este estudio transversal se incluyeron 62 pacientes (hombres: 40 [64,5%], edad media  $51 \pm 13$  años). Los niveles séricos de carnitina total y libre se determinaron mediante ELISA. Los niveles plasmáticos de omega-3 (ácido eicosapentaenoico [EPA], ácido docosahexaenoico [DHA]) y omega-6 (ácido araquidónico [AA], ácido dihomo gamma linoleico [DGLA]) se midieron utilizando LC-ESI-MS/MS. Según las puntuaciones de la Evaluación Cognitiva de Montreal (MoCA),  $\leq 24$  indican CI. Las puntuaciones MoCA  $\leq 24$  y  $> 24$  se determinaron como grupo 1 y grupo 2, respectivamente.

**Resultados:** El grupo 1 tenía proporciones de AA + DGLA/EPA + DHA significativamente más altas y niveles más bajos de carnitina libre, DHA y EPA + DHA en comparación con el grupo 2 ( $p = 0,008$ ,  $p = 0,040$ ,  $p = 0,032$  y  $p = 0,032$ , respectivamente). El grupo 1 tenía un nivel educativo estadísticamente más bajo ( $p < 0,05$ ). Se descubrió una correlación negativa entre las puntuaciones de MoCA y las proporciones AA + DGLA/EPA + DHA ( $r_s = -0,284$ ,  $p = 0,026$ ). Los niveles de carnitina libre se correlacionaron positivamente con los niveles de EPA y EPA + DHA ( $r_s = 0,278$ ,  $p = 0,030$ , y  $r_s = 0,271$ ,  $p = 0,034$ , respectivamente), y negativamente con las proporciones AA + DGLA/EPA + DHA ( $r_s = -0,414$ ,  $p = 0,001$ ). En el análisis de regresión logística multivariante las puntuaciones de MoCA se asociaron con las proporciones AA + DGLA/EPA + DHA ( $p = 0,009$ ) y con el nivel educativo ( $p < 0,001$ ).

**Conclusión:** Se determinó que una alta relación AA + DGLA/EPA + DHA y un bajo nivel educativo podrían ser factores de riesgo independientes del CI. Se ha demostrado que el nivel de carnitina libre puede tener efectos positivos en las distribuciones plasmáticas de EPA + DHA y AA + DGLA. Los niveles bajos de ácidos grasos omega-3 pueden estar asociados con el CI en pacientes en hemodiálisis, y los niveles bajos de carnitina pueden contribuir parcialmente a este proceso. Además, los programas de educación cognitiva pueden tener un efecto en la prevención del CI en pacientes en hemodiálisis con bajos niveles educativos.

© 2022 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Cognitive impairment (CI) is chronic and progressive disablement of cognitive functions beyond what is expected in the normal aging process. CI may progress to dementia, and is associated with an increased risk of disability and health care expenditures.<sup>1</sup> Chronic kidney disease (CKD) is an increased risk factor for CI and it has been demonstrated that there is a correlation between the severity of CKD and CI.<sup>2</sup> Because, CI was detected in about 70% of middle-aged and elderly hemodialysis patients compared to the age-compatible general population.<sup>3</sup> The probable causes of CI in this patient population are explained as vascular damage to brain tissue and direct neurotoxic effects of uremic toxins.<sup>4</sup> Nowadays, the Montreal Cognitive Assessment (MoCA) can be used as a reliable method in the diagnosis and follow-up of CI in hemodialysis patients.<sup>5</sup>

L-Carnitine (3-hydroxy-4-N-trimethyl-aminobutyric acid), a low-molecular-weight amino acid derivative, is crucial for the-oxidation of long-chain fatty acids. It is the cofactor that mediates the entry of long-chain fatty acids into the

mitochondria during the energy production process, and inhibits the accumulation of toxic fatty acids in the mitochondria in some pathological situations that can cause oxidative stress.<sup>6</sup> Kidneys also play an important role in L-carnitine metabolism (expression, secretion, reabsorption).<sup>7</sup> Carnitine homeostasis is disrupted in patients undergoing maintenance hemodialysis, and the carnitine level in plasma and tissues decreases due to both decreased protein intake and the removal of carnitine by dialysis.<sup>8</sup>

Omega-3 long chain polyunsaturated fatty acids are essential fatty acids, and their main source is sea foods. These fatty acids mediate a number of key biological processes such as eicosanoid production, the effects of cell membranes on signal transduction pathways, and modulation of inflammation. Long-chain omega-6 fatty acids are also essential fatty acids, are most abundant in meat and meat products, and have pro-inflammatory and pro-oxidant effects competitively against the anti-inflammatory effects of omega-3 fatty acids.<sup>9-11</sup> It is emphasized that omega-3/omega-6 fatty acids balance is deteriorated in favor of omega-6 fatty acids due to decreases in some enzyme activities such as desaturase in hemodialysis patients,<sup>11</sup> and this situation can be partially corrected by

both omega-3 fatty acids<sup>12</sup> and L-carnitine treatment.<sup>13</sup> In previous studies on dialysis patients, calculations were made on the ratios of omega-3 and omega-6 fatty acids, especially due to their opposite effects on the inflammatory process.<sup>12–14</sup> In addition, low plasma omega 3/omega-6 fatty acid ratios have been shown to be associated with CI.<sup>15</sup>

Recently, positive effects of L-carnitine<sup>16,17</sup> and omega-3 fatty acids<sup>18,19</sup> on cognitive functions have been reported. However, there is not enough data in the literature on the effect of carnitine and fatty acids on cognitive functions in patients with CKD. According to an experimental CKD rat model, it has been shown that administration of L-carnitine can provide a significant improvement in cognitive function.<sup>20</sup> In a recent study in hemodialysis patients, it was emphasized that long-term L-carnitine treatment can reduce white matter microstructural damage and CI.<sup>21</sup> We considered that carnitine and omega-3 fatty acids may have positive effects on CI observed in hemodialysis patients. Therefore, in the study, it was aimed to evaluate the relationship between serum total carnitine, free carnitine, and plasma omega-3 [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] and omega-6 [arachidonic acid (AA) and dihomo-gamma-linolenic acid (DGLA)] fatty acid levels and ratios with cognitive functions that was determined according to the MoCA in patients undergoing maintenance hemodialysis.

## Material and method

### Study design and participants

Sixty two patients undergoing maintenance hemodialysis in the nephrology clinic between March 2017 and February 2018 were included in this cross-sectional study. The study was designed in accordance with the 2018 Declaration of Helsinki, and was approved by the local ethics committee (Protocol date/number; 10.02.2017/2017-02). After all participants were informed about the study in detail, their written informed consent was obtained.

Communication insufficiency or visual, auditory and motor dysfunctions preventing MoCA test, cerebrovascular event, history of psychiatric (anxiety, depression, etc.) disease, frequent intradialytic hypotension attacks (systolic and/or diastolic blood pressures < 90/50 mmHg) non-compliance with HD treatment, severe anemia, decompensated heart failure, liver failure, active infection, thyroid dysfunction, malignancy, use of alcohol-narcotic drug, fish oil containing and antioxidant products were accepted as the exclusion criteria of this study.

Medical histories and demographic data were obtained from the medical records of the patients. Current medical treatments, smoking, co-morbid diseases, presence of renal residue, dialysis durations, systolic and diastolic blood pressures were recorded.

Hemodialysis protocols of the patients were applied as three times a week for 4 h, dialysate flow rate 500 mL/min and blood flow rate 250–350 mL/min using bicarbonate dialysis solution and low/mid-flux polysulphone dialyzer ( $\geq 1.4 \text{ m}^2$ ). Body mass index (BMI) was calculated. The education levels of the patients were grouped as the first five years (primary

school), 6–11 years (secondary school), and 12 and above (high school and university education), respectively. In addition, patients who received L-carnitine treatment (patients given 1 g intravenous L-carnitine after each hemodialysis session for more than 3 months) due to muscle cramps that developed on dialysis, CKD-related anemia resistant to erythropoietin treatment, and weakness and those who did not receive L-carnitine treatment were determined.

### Biochemical analysis procedures

Blood samples of the participants were taken after an overnight fasting, before the second hemodialysis session. After the MoCA test was performed, blood samples were taken as soon as possible. Blood samples taken into tubes with clota activator were kept at room temperature for 30 min, and then centrifuged at  $1310 \times g$  for 10 min. Biochemical parameters were analyzed from the obtained serum samples [blood urea nitrogen, serum creatinine, glucose, sodium, potassium, calcium, phosphorus, bicarbonate, uric acid, albumin, alanine aminotransferase, lipids, ferritin, parathormone and c-reactive protein (CRP)]. While complete blood count analysis was performed with one of the blood samples taken into tubes containing K2-EDTA, the other K2-EDTA containing blood sample was used to get plasma sample after the centrifugation at  $582 \times g$  for 10 min. In addition, blood samples were taken into the tubes with clot activator at the end of dialysis to measure the post-dialysis blood urea nitrogen levels. Serum and plasma samples that were allocated for the determination of total/free carnitine, omega-3 and omega-6 fatty acid levels were stored at  $-80^\circ\text{C}$  until the analysis day.

Beckman Coulter AU 5800 and MindrayBC-6800 devices were used for the measurement of routine biochemical and hematological parameters, respectively. Serum CRP level was measured by nephelometric method. Hemodialysis adequacy was determined by calculating single pool Kt/Vurea ( $\text{spKt/Vurea}$ ) and urea reduction rates (URR).<sup>22</sup>

Human total and free carnitine serum concentrations were determined by the Enzyme-Linked Immunosorbent Assay (ELISA) method using commercially available kits (Shanghai YL Biotech Co., Ltd., Catalog No: YLA0451HU and Shanghai YL Biotech Co., Ltd., Catalog No: YLA0226HU). The intra-assay and inter-assay coefficients of variation for total and free serum carnitine assays were 8% and 10%, respectively. The sensitivity of total and free serum carnitine analyzes were 0.52 nmol/mL and 0.21 nmol/mL, respectively. Total and free serum carnitine test ranges were 1–300 nmol/mL, and 0.5–200 nmol/mL, respectively. Omega 3 and omega 6 fatty acids were measured using electrospray ionization (ESI) technique in multiple reaction monitoring (MRM) mode by the LC-MS/MS device (Thermo Scientific TSQ Quantum Access Max) by modifying the method of Valianpour et al.<sup>23</sup>

### MoCA procedure and evaluation

The MoCA is a short screening test consisting of 12 items, lasting approximately 10–15 min and achieving a maximum of 30 points, in which parameters such as visuospatial and executive functions (5 points), naming (3 points), language (3 points), attention (6 points), abstract thinking (2 points), short-term

memory/recall (5 points), orientation (6 points) can be evaluated. The Turkish version of this test, which has been shown to be reliable and effective, was used in the study.<sup>24</sup> Since the cognitive performance of hemodialysis patients may be affected by the fluid variability that occurs during dialysis, the MoCA tests were performed in a separate room before dialysis. While determining the MoCA score, similar to previous studies in hemodialysis patients, one point was added to the total score of those with an education level of  $\leq 11$  years, and  $\leq 24$  points were considered as CI.<sup>5,21</sup> According to the total score of the MoCA, two groups were formed as  $\leq 24$  and  $>24$ , and then their demographic, clinical and laboratory characteristics were compared.

### Statistical analysis

IBM SPSS 23 package program was used for statistical analysis. Shapiro–Wilk test was used to determine whether the groups were normally distributed. While categorical variables were given as numbers and percentages, continuous variables with normal distribution were given as mean  $\pm$  standard deviation and continuous variables not showing normal distribution were given as median (25–75th quartile). While Student's *t*-test was used to determine whether the normally distributed continuous variables showed a statistically significant difference between the two groups, the Mann–Whitney *U* test was used to determine whether the continuous variables that did not show a normal distribution showed a statistically significant difference between the two groups. Spearman correlation analysis was performed to determine the relationships between parameters. Univariate and multivariate logistic regression analyses were used to determine which parameters affect the cognitive functions.  $P < 0.05$  was considered statistically significant.

## Results

The mean age of 62 hemodialysis patients (40 males, 64.5%) was  $51 \pm 13$  years. The number of patients with an education level of 12 years was 9 (14.5%), and the number of patients who received 1 g of intravenous L-carnitine treatment after each hemodialysis session was 22 (35.5%). There was no statistically significant difference between total and free carnitine levels of patients who received L-carnitine treatment and those who did not [38.6 (14.4–93.4) nmol/mL vs. 33.1 (17.2–68.0) nmol/mL,  $P = 0.971$ , and 26.4 (13.1–42.1) nmol/mL vs. 23.1 (15.3–40.1) nmol/mL,  $P = 0.930$ , respectively]. The mean MoCA total score of all patients was 20.5. Details of the demographic, clinical and laboratory data of the patients are presented in [Tables 1 and 2](#).

In the MoCA test, when the threshold value for determining CI was taken as 24 points, the total score was found to be  $\leq 24$  in 43 (69.4%) of the patients (Group 1), while the total score was found to be  $>24$  in 19 (30.6%) of the patients (Group 2). In Group 1, the female gender was statistically significantly higher ( $P = 0.006$ ), and education levels were significantly lower (1–5 years,  $P < 0.001$ ; 6–11 years,  $P = 0.019$ ;  $\geq 12$  years,  $P = 0.002$ , respectively). While there was no statistically significant difference for L-carnitine treatment between the

**Table 1 – Basic characteristics of the patients.**

Variables	Patients (n = 62)
Gender, male, n (%)	40 (64.5)
Age, years	$51 \pm 13$
Residential (urban/rural), n (%)	42/20 (67.7/32.3)
Education level, n (%)	
1–5 years	36 (58.1)
6–11 years	17 (27.4)
$\geq 12$ years	9 (14.5)
Hypertension, n (%)	45 (72.6)
Diabetes Mellitus, n (%)	14 (22.6)
Current smoker, n (%)	22 (35.5)
Systolic blood pressure, mmHg	$129 \pm 24$
Diastolic blood pressure, mmHg	$78 \pm 13$
Body mass index, kg/m <sup>2</sup>	$25.5 \pm 5.2$
Dialysis vintage, month	52.5 (21.0–116.2)
Renal residual volume, n (%)	17 (27.4)
Medical treatments, n (%)	
L-Carnitine	22 (35.5)
Iron sucrose	39 (62.9)
Erythropoietin	43 (69.4)
Vitamin D	18 (29)
Antiagregant	30 (48.4)
Statin	5 (8.1)
Phosphorus binder	46 (74.2)
Montreal cognitive assessment (MoCA) score (point)	
Visual spatial/Executive (0–5)	3 (2–5)
Naming (0–3)	3 (2–3)
Attention (0–6)	4 (2–4)
Language (0–3)	1 (0–3)
Abstraction (0–2)	1 (0–2)
Delayed recall (0–5)	1 (0–2.3)
Orientation (0–6)	6 (5–6)
Total score (0–30)	20.5 (14.0–24.25)

Categorical data are presented as frequencies and percentages; continuous variables are presented as mean  $\pm$  standard deviations or median and (25–75th quartile) depending on their distributions.

groups ( $P = 0.669$ ), serum free carnitine levels were found to be statistically significantly higher in Group 2 ( $P = 0.040$ ). However, although the serum total carnitine level was numerically higher in Group 2, it did not reach statistical significance ( $P = 0.072$ ). While plasma DHA and EPA + DHA levels were statistically significantly higher in Group 2 ( $P = 0.032$ ,  $P = 0.032$ , respectively), plasma AA + DGLA/EPA + DHA ratio was found to be statistically significantly lower ( $P = 0.008$ ). In addition, all specific cognitive function scores of Group 1 were statistically significantly lower than Group 2 ( $P < 0.05$ ). Details of demographic and clinical data between groups are shown in [Tables 3 and 4](#).

When the comparison was made by gender, statistically significant lower MoCA score, education level, serum creatinine level ( $P < 0.001$ ,  $P = 0.003$ ,  $P = 0.005$ , respectively), and higher spKt/Vurea and URR were detected in women ( $P < 0.001$ ,  $P < 0.001$ , respectively). The plasma AA + DGLA/EPA + DHA ratio was found to be significantly higher in women [4.12 (2.63–5.69) vs. 4.76 (4.29–5.81),  $P = 0.050$ ].

When correlation analysis of variables associated with MoCA total scores was performed, age ( $r_s = -0.410$ ,  $P = 0.001$ ), gender ( $r_s = -0.538$ ,  $P < 0.001$ ), education level

**Table 2 – Laboratory characteristics of the patients.**

Variables	Patients (n = 62)
BUN, mg/dL	75 ± 13
Creatinine, mg/dL	10.2 (7.9–11.6)
spKt/Vurea	1.56 ± 0.29
URR, (%)	72 ± 6
Glucose, mg/dL	90(81–125)
Sodium, mEq/L	139 ± 3
Potassium, mEq/L	5.4 ± 0.6
Calcium, mg/dL	8.7 ± 0.7
Phosphorus, mg/dL	5.4 ± 1.3
Albumin, g/dL	3.9 ± 0.3
ALT, U/L	10(7–15)
Uric acid, mg/dL	7.3 ± 1.1
Triglyceride, mg/dL	174(118–239)
LDL-C, mg/dL	90(73–115)
Bicarbonate, mmol/L	21.3 ± 2.6
Hemoglobin, g/dL	10.9 ± 1.9
Ferritin, ng/mL	738(507–1038)
Parathormone, pg/mL	429(253–696)
CRP, mg/dL	6.0 (3.12–11.9)
Total carnitine, nmol/mL	36.1 (16.4–79.3)
Free carnitine, nmol/mL	25.0 (15.0–42.2)
EPA, mg/L	15.3 (10.3–50.7)
DHA, mg/L	28.2 (19.9–89.0)
EPA + DHA, mg/L	54.8 (30.2–147.2)
DGLA, mg/L	46.1 (29.2–80.2)
AA, mg/L	137(90–377)
DGLA + AA, mg/L	184(114–644)
DGLA + AA/EPA + DHA	4.51 (3.24–5.72)

Categorical data are presented as frequencies and percentages; continuous variables are presented as mean ± standard deviations or median and (25–75th quartile) depending on their distributions.

Abbreviations: AA, arachidonic acid; ALT, alanine aminotransferase; BUN, blood urea nitrogen; CRP, c-reactive protein; DGLA, dihomogamma linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LDL-C, low density lipoprotein cholesterol; spKt/V (üre), single pool Kt/Vurea (urea kinetic model); URR, urea reduction rate.

( $r_s = 0.694$ ,  $P < 0.001$ ), spKt/Vurea ( $r_s = -0.398$ ,  $P = 0.001$ ), URR ( $r_s = -0.390$ ,  $P = 0.002$ ), albumin ( $r_s = 0.296$ ,  $P = 0.019$ ) and plasma AA + DGLA/EPA + DHA ratio ( $r_s = -0.284$ ,  $P = 0.026$ ) were found to be correlated. There was no statistically significant correlation between MoCA total scores and taking L-carnitine treatment, serum total and free carnitine levels. ( $r_s = -0.083$ ,  $P = 0.521$ ;  $r_s = 0.176$ ,  $P = 0.171$ ;  $r_s = 0.206$ ,  $P = 0.108$ , respectively). However, there was a statistically significant positive correlation between serum free carnitine levels and plasma EPA and EPA + DHA levels ( $r_s = 0.278$ ,  $P = 0.030$  and  $r_s = 0.271$ ,  $P = 0.034$ , respectively). In addition, statistically significant negative correlation was found between serum total and free carnitine levels and plasma AA + DGLA/EPA + DHA ratio ( $r_s = -0.363$ ,  $P = 0.004$  and  $r_s = -0.414$ ,  $P = 0.001$ , respectively). Details of the correlation analyzes mentioned above are presented in [Tables 5 and 6](#).

When logistic regression analyses are performed, MoCA total score has a significant relationship with gender ( $P = 0.013$ ), education level ( $P < 0.001$ ), albumin ( $P = 0.027$ ), EPA ( $P = 0.034$ ), DHA ( $P = 0.045$ ), EPA + DHA ( $P = 0.031$ ) and AA + DGLA/EPA + DHA ratio ( $P = 0.002$ ) in univariate logistic regression analysis, whereas in multivariate logistic

regression analysis MoCA total score was correlated with education level ( $P < 0.001$  and AA + DGLA/EPA + DHA ratio ( $P = 0.009$ ) ([Table 7](#)).

## Discussion

In this study, it was determined that CI was common according to the MoCA test in patients undergoing maintenance hemodialysis. This result was similar to previous studies in which cognitive function assessment was performed with the same method in hemodialysis patients.<sup>5,25</sup> It was shown that CI was correlated with age, gender, education level, dialysis efficiency, albumin level and AA + DGLA/EPA + DHA ratio. However, it was found that the relationship between education level and AA + DGLA/EPA + DHA ratio with cognitive impairment continued in the other variable adjustments were done.

In our study, similar to previous studies, it was shown that low education level is associated with poor cognitive function.<sup>5,25</sup> The significant gender difference between the groups can be explained by the fact that the education level of women in the study is lower than that of men, and this situation negatively affects the cognitive functions of women. In general population based studies, it is emphasized that CI is higher in women compared to men,<sup>26</sup> and this may be related to the socioeconomic status.<sup>27</sup> Although our study results show that education level has an important effect on cognitive functions, it suggests that there are other risk factors for CI in this patient population, especially in women.

Another result of our study is that the spKt/Vurea and URR values were higher in Group 1 and women, although they did not reach statistical significance. In addition, negative correlations were found between MoCA total scores and spKt/Vurea and URR values in all patients. These results show that increased dialysis dose is not associated with better cognitive function, and even similar to the results of previous studies, high Kt/Vurea value may be associated with worse cognitive function.<sup>28,29</sup> The authors stated that this finding can be explained by the fact that patients with high Kt/Vurea were generally weaker than normal and had worse nutrition. In our study, it was determined that low serum albumin level, which is an important indicator of poor nutritional status in hemodialysis patients,<sup>30</sup> may be associated with CI. It was also considered that wide fluctuations in fluid, osmolarity and uremic toxin levels that may occur due to more intense hemodialysis in these patients may adversely affect cognitive functions. This relationship between serum albumin level, dialysis dose and cognitive functions was not observed in logistic regression analyses. However, the data support that higher spKt/Vurea is not associated with better cognitive function.

Carnitine, an essential cofactor for normal fatty acid metabolism, has shown beneficial effects on brain tissue. L-carnitine is known to contribute to the formation of acetyl carnitine and acetylcholine by mediating the passage of acetyl particles from mitochondria to cytosol in brain tissue.<sup>16</sup> Acetyl carnitine shows neurobiological effects with synaptic morphology, synaptic transmission of many neurotransmitters, phospholipid metabolism, and brain energy modulation.<sup>31</sup> It has been demonstrated that L-carnitine treatment can affect

**Table 3 – Comparison of demographic and somatometric data of the groups.**

Variables	Group 1 (n=43)	Group 2 (n=19)	P
Gender; male, n (%)	23 (53.5)	17 (89.5)	0.006
Age, years	51.5 ± 12.3	46.1 ± 13.2	0.144
Residential (urban/rural), n (%)	30/13 (69.8/30.2)	12/7 (63.2/36.8)	0.608
Education level, n (%)			
1–5 years	33 (76.7)	3 (15.8)	<0.001
6–11 years	8 (18.6)	9 (47.4)	0.019
≥12 years	2 (4.7)	7 (36.8)	0.002
Hypertension, n (%)	32 (74.4)	13 (68.4)	0.626
Diabetes Mellitus, n (%)	9 (20.9)	5 (26.3)	0.744
Current smoker, n (%)	14 (32.6)	8 (42.1)	0.469
Systolic blood pressure, mmHg	130 ± 27	124 ± 18	0.341
Diastolic blood pressure, mmHg	78 ± 14	77 ± 10	0.818
Body mass index, kg/m <sup>2</sup>	25.4 ± 5.03	25.8 ± 5.79	0.786
Dialysis vintage, month	60 (12–120)	52 (25–96)	0.593
Renal residual volume, n (%)	10 (23.3)	7 (36.8)	0.269
Medical treatments, n (%)			
L-Carnitine	16 (37.2)	6 (31.6)	0.669
Iron sucrose	28 (65.1)	11 (57.9)	0.587
Erythropoietin	32 (74.4)	11 (57.9)	0.193
Vitamin D	12 (27.9)	6 (31.6)	0.769
Antiagregan	19 (44.2)	11 (57.9)	0.879
Statins	5 (11.6)	0 (0)	0.312
Phosphorus binder	30 (69.8)	16 (84.2)	0.347
Specific cognitive functions (point)			
Visuospacial/executive	3 (1–3)	5 (4–5)	<0.001
Naming	3 (2–3)	3 (3–3)	0.005
Attention	3 (1–6)	6 (5–6)	<0.001
Language	1 (0–2)	3 (2–3)	<0.001
Abstraction	0 (0–1)	2 (2–2)	<0.001
Delayed recall	0 (0–2)	2 (1–4)	<0.001
Orientation	6 (5–6)	6 (6–6)	0.002

Categorical data are presented as frequencies and percentages; continuous variables are presented as mean ± standard deviations or median and (25th-75th quartile) depending on their distributions.

**Table 4 – Comparison of the laboratory data of the groups.**

Variables	Group 1 (n=43)	Group 2 (n=19)	P
BUN, mg/dL	75 ± 12	74 ± 13	0.700
Creatinine, mg/dL	9.3 ± 2.4	10.8 ± 2.3	0.031
spKt/Vurea	1.6 ± 0.32	1.48 ± 0.17	0.053
URR, (%)	72 ± 7	71 ± 6.4	0.347
Glucose, mg/dL	89(79–122)	106(82–29)	0.479
Sodium, mEq/L	139 ± 3	140 ± 2	0.223
Potassium, mEq/L	5.38 ± 0.66	5.31 ± 0.51	0.676
Calcium, mg/dL	8.64 ± 0.74	8.78 ± 0.61	0.479
Phosphorus, mg/dL	5.42 ± 1.27	5.43 ± 1.33	0.976
Albumin, g/dL	3.84 ± 0.32	4.06 ± 0.33	0.020
ALT, U/L	10(7–15)	10(7–14.5)	0.782
Uric acid, mg/dL	7.2 ± 1.2	7.4 ± 0.9	0.396
Triglyceride, mg/dL	167(101–235)	191(125–333)	0.255
LDL-c, mg/dL	82(67–107)	115(80–132)	0.014
Bicarbonate, mmol/L	21.5 ± 2.74	20.7 ± 2.19	0.215
Hemoglobin, g/dL	10.7 ± 2.1	11.5 ± 1.2	0.110
Ferritin, ng/mL	417(250–640)	471(269–713)	0.468
Parathormone, pg/mL	417(250–640)	471(269–713)	0.879
CRP, mg/dL	6.5 (3.1–16.3)	4.7 (1.4–8.3)	0.044
Total carnitine, nmol/mL	21.7 (13.1–39.4)	37.1 (17.8–46.6)	0.072
Free carnitine, nmol/mL	12.8 (10.3–34.0)	36.6 (10.9–113)	0.040

Table 4 (Continued)

Variables	Group 1 (n = 43)	Group 2 (n = 19)	P
EPA, mg/L	12.8 (10.3–34.0)	36.6 (10.9–113)	0.094
DHA, mg/L	23.8 (18.3–67.9)	67.4 (29.2–243)	0.032
EPA + DHA, mg/L	39.2 (29.1–107)	96.0 (48.8–243)	0.032
DGLA, mg/L	49.8 (35.5–89.0)	40.3 (17.1–64.6)	0.075
AA, mg/L	136(103–380)	145(69–269)	0.275
DGLA + AA, mg/L	184(140–473)	185(96–337)	0.242
AA + DGLA/EPA + DHA	4.74 (3.62–5.88)	3.37 (0.51–4.66)	0.008

Categorical data are presented as frequencies and percentages; continuous variables are presented as mean  $\pm$  standard deviations or median and (25–75th quartile) depending on their distributions.

Abbreviations: AA, arachidonic acid; ALT, alanine aminotransferase; BUN, blood urea nitrogen; CRP, c-reactive protein; DGLA, dihomo-gamma linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LDL-C, low density lipoprotein cholesterol; spKt/V (üre), single pool Kt/Vure (urea kinetic model); URR, urea reduction rate.

the central nervous system, and slow down CI by increasing serum concentrations of both L-carnitine and acetyl carnitine.<sup>32</sup> It has been shown that serum carnitine levels of patients undergoing maintenance hemodialysis are significantly lower.<sup>8</sup> In a study of Zhang et al.,<sup>33</sup> it was emphasized that low total and free carnitine levels in hemodialysis patients can increase with L-carnitine treatment, and dialysis related complications can be reduced by determining the appropriate plasma free carnitine level. The data of our study suggest that low serum free carnitine level may be associated with poor cognitive functions. Also, the fact that carnitine levels were not different between those who received and did not receive L-carnitine therapy, suggesting that those who received L-carnitine therapy had lower carnitine levels at the beginning of treatment. In an experimental study on this subject, it was shown that administration of L-carnitine to rats with CKD provided significant improvement in cognitive functions, and it was stated that this effect could be achieved by the antioxidant property, the energy need of the cells, and regulating the changes in membrane phospho lipid metabolism.<sup>20</sup> In a recent study, it was revealed that L-carnitine may exert a neuroprotective effect by suppressing neuroinflammation against white matter microstructural damage and cognitive deterioration in hemodialysis patients.<sup>21</sup> Although the available data support the use of L-carnitine in the treatment of CI in this patient population, the mechanisms of the effect of L-carnitine on cognitive functions should be revealed in detail.

Nowadays, it is stated that EPA and DHA can have neuroprotective effects. In brain tissue, DHA, main long-chain fatty acid of phospholipids, may prevent or correct CI when they are taken with diet for a long time.<sup>18,19</sup> In hemodialysis patients, it was found that plasma omega-3/omega-6 fatty acid distribution changes abnormally, and plasma/cell phospholipids have lower EPA and DHA concentration.<sup>17,34</sup> It was thought that this situation may be related to the scarcity of sea food taken in the diet of hemodialysis patients, the decrease in the functions of elongase and desaturase enzymes, malabsorption, and omega-3 fatty acid loss from dialysate.<sup>35,36</sup>

In our study, a significant relationship was found between lower MoCA scores and high AA + DGLA/EPA + DHA ratio in hemodialysis patients. This finding supports that there may be a relationship between the decrease in omega-3 fatty acid ratios and CI in hemodialysis patients. In addition, higher AA + DGLA/EPA + DHA ratio in females compared to males in

Table 5 – Correlation analysis of MoCA total scores and variables.

Variables	MoCA total scores (n = 62)	
	$r_s$	P
Age	–0.410	0.001
Gender	–0.538	<0.001
Education level	0.694	<0.001
L-Carnitine therapy	–0.083	0.521
spKt/Vurea	–0.398	0.001
URR	–0.390	0.002
Albumin	0.296	0.019
LDL-C	0.214	0.101
CRP	–0.190	0.140
EPA	0.109	0.402
DHA	0.225	0.081
EPA + DHA	0.211	0.102
AA	–0.111	0.396
DGLA	–0.214	0.098
AA + DGLA	–0.131	0.316
AA + DGLA/EPA + DHA	–0.284	0.026
Total carnitine	0.176	0.171
Free carnitine	0.206	0.108

Significance was determined by Sperman rank correlation coefficient.

Abbreviations: AA, arachidonic acid; CRP, c-reactive protein; DGLA, dihomo-gamma linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LDL-C, low density lipoprotein cholesterol; spKt/V (üre), single pool Kt/Vure (urea kinetic model); URR, urea reduction rate.

our study may contribute causally to higher CI in females. Possible reasons for this situation are, as stated in a recent study, lower consumption of food containing omega-3 fatty acids in women,<sup>36</sup> worse nutritional status of female patients lower serum albumin levels or greater omega-3 fatty acid loss with higher dialysis dose related dialysate. The positive correlation of serum free carnitine level with EPA and DHA, and negative correlation with AA + DGLA/EPA + DHA ratio show that L-carnitine can also be effective on the regulation of omega-3 fatty acid metabolism and the preservation of cognitive functions.

Our study has some limitations. It is difficult to generalize according to our findings, since it is a single-center, non-randomized study with a relatively small sample size. In addition, due to its cross-sectional design, cause and effect

**Table 6 – Correlation analysis of serum carnitine levels with fatty acids.**

Variables	Total carnitine		Free carnitine	
	$r_s$	P	$r_s$	P
EPA	0.211	0.102	0.278	0.030
DHA	0.185	0.153	0.245	0.057
EPA + DHA	0.204	0.114	0.271	0.034
AA	0.021	0.872	0.054	0.679
DGLA	0.021	0.872	0.049	0.706
AA + DGLA	0.014	0.916	0.047	0.717
AA + DGLA/EPA + DHA	-0.363	0.004	-0.414	0.001

Significance was determined by Spearman rank correlation coefficient.

Abbreviations: AA, arachidonic acid; DGLA, dihomo-gamma linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.

**Table 7 – Variables associated with MoCA total score in univariate and multivariate logistic regression analysis.**

Variables	Univariate			Multivariate		
	OR (%95 CI min-max)	Wald	P	OR(%95CImin – max)	Wald	P
Gender	7.391 (1.518–35.991)	6.134	0.013			
Education level	7.154 (2.645–19.351)	15.020	<0.001	6.292 (2.276–17.397)	12.563	<0.001
Albumin	8.967 (1.287–62.496)	4.903	0.027			
EPA	1.011 (1.001–1.021)	4.479	0.034			
DHA	1.010 (1.000–1.019)	4.033	0.045			
EPA + DHA	1.006 (1.001–1.011)	4.645	0.031			
AA + DGLA/EPA + DHA	0.575 (0.407–0.813)	9.793	0.002	0.585 (0.390–0.877)	6.739	0.009

Abbreviations: AA, arachidonic acid; DGLA, dihomo-gamma linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; CI, confidence interval; OR, odds ratio (estimated).

association should be done carefully. In our study, it was accepted that cognitive functions were impaired in patients with a MoCA total score of 24 points, and no distinction was made between mild-moderate CI and dementia, since patients with dementia were excluded from the study. Although there was no statistical difference in the proportions of patients receiving L-carnitine therapy between the groups, receiving this therapy likely affected serum total and free carnitine levels. Finally, since plasma fatty acid distribution may be affected by diet and dietary fatty acid intake, this could be further evaluated with nutritional intake analyzes. Despite these limitations, the specificity of the study group constitutes the strength of our study.

## Conclusion

As a result, the prevalence of CI according to the MoCA was found to be high in hemodialysis patients. Low education level and high plasma AA + DGLA/EPA + DHA ratio were determined to be independent risk factors associated with CI. It has been shown that serum carnitine levels may have positive effects on plasma EPA + DHA and AA + DGLA distributions in these patients. According to our findings, it can be said that low omega-3 fatty acid levels in hemodialysis patients may be associated with the onset and progression of CI, and that low carnitine levels may partially contribute to this process. Assessment of cognitive functions in these patients especially those with low education level can be included in routine clinical practice, and symptoms associated with CI can be improved with omega-3 fatty acid and carnitine supplementation in patients with CI. In addition, data support

that cognitive education programs should be applied to prevent or reduce cognitive impairment in hemodialysis patients with low education levels. However, our findings should be confirmed by prospective studies with large participation.

## Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Conflict of interest

The authors declare that they have no conflict of interests.

## REFERENCES

- Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of cognitive impairment without dementia in the United States. *Ann Intern Med.* 2008;148:427–34, <http://dx.doi.org/10.7326/0003-4819-148-6-200803180-00005>.
- Kurella M, Chertow GM, Fried LF, Cummings SR, Harris T, Simonsick E, et al. Chronic kidney disease and cognitive impairment in the elderly: the Health, Aging, and Body Composition Study. *J Am Soc Nephrol.* 2005;16:2127–33, <http://dx.doi.org/10.1681/ASN.2005010005>.
- O'Lone E, Connors M, Masson P, Wu S, Kelly PJ, Gillespie D, et al. Cognition in people with end-stage kidney disease treated with hemodialysis: a systematic review and



- meta-analysis. *Am J Kidney Dis.* 2016;67:925–35, <http://dx.doi.org/10.1053/j.ajkd.2015.12.028>.
4. Bugnicourt JM, Godefroy O, Chillon JM, Choukroun G, Massy ZA. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. *J Am Soc Nephrol.* 2013;24:353–63, <http://dx.doi.org/10.1681/ASN.2012050536>.
  5. Tian R, Guo Y, Ye P, Zhang C, Luo Y. The validation of the Beijing version of the Montreal Cognitive Assessment in Chinese patients undergoing hemodialysis. *PLOS ONE.* 2020;15:e0227073, <http://dx.doi.org/10.1371/journal.pone.0227073>.
  6. Marcovina SM, Sirtori C, Peracino A, Gheorghide M, Borum P, Remuzzi G, et al. Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. *Transl Res.* 2013;161:73–84, <http://dx.doi.org/10.1016/j.trsl.2012.10.006>.
  7. Wanner C, Horl WH. Carnitine abnormalities in patients with renal insufficiency. Pathophysiological and therapeutical aspects. *Nephron.* 1988;50:89–102, <http://dx.doi.org/10.1159/000185137>.
  8. Bene J, Csiky B, Komlosi K, Sulyok E, Meleg B. Dynamic adaptive changes of the serum carnitine esters during and after L-carnitine supplementation in patients with maintenance haemodialysis. *Scand J Clin Lab Invest.* 2011;71:280–6, <http://dx.doi.org/10.3109/00365513.2011.560674>.
  9. Oh DY, Talukdar S, Bae EJ, Bae EJ, Imamura T, Morinaga H, et al. Gpr120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin sensitizing effects. *Cell.* 2010;142:687–98, <http://dx.doi.org/10.1016/j.cell.2010.07.041>.
  10. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. *Nat Immunol.* 2005;6:1191–7, <http://dx.doi.org/10.1038/ni1276>.
  11. An WS, Kim SE, Kim KH, Lee S, Park Y, Kim HJ, et al. Comparison of fatty acid contents of erythrocyte membrane in hemodialysis and peritoneal dialysis patients. *J Ren Nutr.* 2009;19:267–74, <http://dx.doi.org/10.1053/j.jrn.2009.01.027>.
  12. An WS, Kim SE, Kim KH, Lee S, Park Y, Kim HJ, et al. Comparison of fatty acid contents of erythrocyte membrane in hemodialysis and peritoneal dialysis patients. *J Ren Nutr.* 2009;19:267–74, <http://dx.doi.org/10.1053/j.jrn.2009.01.027>. PMID: 19539181.
  13. Ahmad S, Dasgupta A, Kenny MA. Fatty acid abnormalities in hemodialysis patients: effect of L-carnitine administration. *Kidney Int Suppl.* 1989; Suppl. 27:243–6.
  14. Shoji T, Kakiya R, Hayashi T, Tsujimoto Y, Sonoda M, Shima H, et al. Serum n–3 and n–6 polyunsaturated fatty acid profile as an independent predictor of cardiovascular events in hemodialysis patients. *Am J Kidney Dis.* 2013;62:568–76, <http://dx.doi.org/10.1053/j.ajkd.2013.02.362>.
  15. Suwa M, Yamaguchi S, Komori T, Kajimoto S, Kino M. The association between cerebral white matter lesions and plasma Omega-3 to Omega-6 polyunsaturated fatty acids ratio to cognitive impairment development. *Biomed Res Int.* 2015;2015:153437, <http://dx.doi.org/10.1155/2015/153437>.
  16. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. *Int Clin Psychopharmacol.* 2003;18:61–71, <http://dx.doi.org/10.1097/00004850-200303000-00001>.
  17. Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M. L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. *Am J Clin Nutr.* 2007;86:1738–44, <http://dx.doi.org/10.1093/ajcn/86.5.1738>.
  18. Yanai H. Effects of n–3 polyunsaturated fatty acids on dementia. *J Clin Med Res.* 2017;9:1–9, <http://dx.doi.org/10.14740/jocmr2815w>.
  19. Cardoso C, Afonso C, Bandarra NM. Dietary DHA and health: cognitive function ageing. *Nutr Res Rev.* 2016;29:281–94, <http://dx.doi.org/10.1017/S0954422416000184>.
  20. Abu Ahmad N, Armaly Z, Berman S, Jabour A, Aga-Mizrachi S, Mosenego-Orman E, et al. L-Carnitine improves cognitive and renal functions in a rat model of chronic kidney disease. *Physiol Behav.* 2016;164:182–8, <http://dx.doi.org/10.1016/j.physbeh.2016.05.036>.
  21. Ueno Y, Saito A, Nakata J, Kamagata K, Taniguchi D, Motoi Y, et al. Possible neuroprotective effects of L-carnitine on white-matter microstructural damage and cognitive decline in hemodialysis patients. *Nutrients.* 2021;13:1292, <http://dx.doi.org/10.3390/nu13041292>.
  22. Kovacic V, Roguljic L, Jukic I, Kovacic V. Comparison of methods for hemodialysis dose calculation. *Dial Transplant.* 2003;32:170–5.
  23. Valianpour F, Selhorst JJ, van Lint LE, van Gennip AH, Wanders RJ, Kemp S. Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry. *Mol Genet Metab.* 2003;79:189–96, [http://dx.doi.org/10.1016/s1096-7192\(03\)00098-2](http://dx.doi.org/10.1016/s1096-7192(03)00098-2).
  24. Kaya Y, Aki OE, Can UA, Derle E, Kibaroglu S, Barak A. Validation of montreal cognitive assessment and discriminant power of montreal cognitive assessment subtests in patients with mild cognitive impairment and Alzheimer dementia in Turkish population. *J Geriatr Psychiatry Neurol.* 2014;27:103–9, <http://dx.doi.org/10.1177/0891988714522701>.
  25. Tiffin-Richards FE, Costa AS, Holschbach B, Frank RD, Vassiliadou A, Krüger T, et al. The Montreal Cognitive Assessment (MoCA) – a sensitive screening instrument for detecting cognitive impairment in chronic hemodialysis patients. *PLOS ONE.* 2014;9:e106700, <http://dx.doi.org/10.1371/journal.pone.0106700>.
  26. Bohlken J, Jacob L, Kostev K. Progression of mild cognitive impairment to dementia in German specialist practices. *Dementia (London).* 2019;18:380–90, <http://dx.doi.org/10.1177/1471301216673919>.
  27. Miyawaki CE, Liu M. Gender differences in cognitive impairment among the old and the oldest-old in China. *Geriatr Gerontol Int.* 2019;19:586–92, <http://dx.doi.org/10.1111/ggi.13666>.
  28. Kurella Tamura M, Larive B, Unruh ML, Stokes JB, Nissenon A, Mehta RL, et al. Prevalence and correlates of cognitive impairment in hemodialysis patients: the Frequent Hemodialysis Network trials. *Clin J Am Soc Nephrol.* 2010;5:1429–38, <http://dx.doi.org/10.2215/CJN.01090210>.
  29. Giang LM, Weiner DE, Agganis BT, Scott T, Sorensen EP, Tighiouart H, et al. Cognitive function and dialysis adequacy: no clear relationship. *Am J Nephrol.* 2011;33:33–8, <http://dx.doi.org/10.1159/000322611>.
  30. Quero Alfonso AI, Fernández Castillo R, Fernández Gallegos R, Gomez Jimenez FJ. Study of serum albumin and BMI as nutritional markers in hemodialysis patients. *Nutr Hosp.* 2014;31:1317–22, <http://dx.doi.org/10.3305/nh.2015.31.3.8084>.
  31. Virmani A, Binienda Z. Role of carnitine esters in brain neuropathology. *Mol Aspects Med.* 2004;25:533–49, <http://dx.doi.org/10.1016/j.mam.2004.06.003>.
  32. Vecchiet L, Di Lisa F, Pieralisi G, Ripari P, Menabò R, Giamberardino MA, et al. Influence of L-carnitine administration on maximal physical exercise. *Eur J Appl Physiol Occup Physiol.* 1990;61:486–90, <http://dx.doi.org/10.1007/BF00236072>.
  33. Zhang YM, Zhuo L, Hu J, Cui G, Zhang L, Zhang XL, et al. Clinical significance of different carnitine levels for improving

- the prognosis of patients undergoing hemodialysis. *Ren Fail.* 2016;38:1654-8, <http://dx.doi.org/10.1080/0886022X.2016.1229967>.
34. Madsen T, Christensen JH, Svensson M, Witt PM, Toft E, Schmidt EB. Marine n-3 polyunsaturated fatty acids in patients with end-stage renal failure and in subjects without kidney disease: a comparative study. *J Ren Nutr.* 2011;21:169-75, <http://dx.doi.org/10.1053/j.jrn.2010.06.020>.
35. Sertoglu E, Kurt I, Tapan S, Uyanik M, Serdar MA, Kayadibi H, et al. Comparison of plasma and erythrocyte membrane fatty acid compositions in patients with end-stage renal disease and type 2 diabetes mellitus. *Chem Phys Lipids.* 2014;178:117, <http://dx.doi.org/10.1016/j.chemphyslip.2013.12.011>.
36. Thompson M, Hein N, Hanson C, Smith LM, Anderson-Berry A, Richter CK, et al. Omega-3 fatty acid intake by age, gender, and pregnancy status in the United States: national health and nutrition examination survey 2003-2014. *Nutrients.* 2019;11:177, <http://dx.doi.org/10.3390/nu11010177>.